Vertebration Inc.
This article was originally published in Start Up
Executive Summary
People who suffer from lower back pain and opt for spinal surgery may soon have another minimally invasive option for filling the space left following the removal of the damaged or diseased disc. By inserting through a much smaller incision than current devices, the expandable XYcor spinal implant from Vertebration has the potential to spare significant trauma to the soft tissue and bone while it provides mechanical support during the fusion process between the vertebra of the spine.
You may also be interested in...
Start-Up Previews (05/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.